New Weight Loss Drugs 2026-2027: What to Expect After Mounjaro and Ozempic

Imagine standing in front of a future pharmacy window. Behind the glass — tablets instead of injections, triple agonists with nearly 25% efficacy, next-generation combination therapies. It looks incredible. But there's one problem. The pharmacy won't open until 2027-2028 at the earliest.

Meanwhile, Mounjaro with proven 22.5% weight loss and Ozempic with 14.9% are already available. Right now. In April 2026. The question isn't whether you should wait for the 'perfect' drug. The question is how many months you're willing to lose while waiting.

Let's examine what's actually happening in the GLP-1 world, which molecules are coming, and why the best time to start is right now.

What's Happening in Weight Loss: The GLP-1 Revolution

The weight loss drug market is experiencing a real explosion. According to analyst projections, the global GLP-1 market will reach $268.4 billion by 2030. This isn't just growth. This is a revolution in approaching obesity as a chronic disease.

After the stunning success of Mounjaro and Ozempic, pharmaceutical giants rushed to develop new molecules. Dozens of potential drugs are currently in Phase 2 and Phase 3. The main development directions are clear.

The first trend is triple agonists. While Mounjaro activates two receptors (GLP-1 and GIP), new molecules target three. Retatrutide (Retatrutide), which we wrote about in detail, showed up to 24.2% weight loss. This is currently the highest result among all drugs.

Second trend — oral forms. Daily injections will be replaced by tablets. And this is no longer science fiction, but the reality of 2026.

Third trend — combination therapies. Two active substances in one injection for synergistic effect.

Fourth trend — muscle-sparing formulas. Drugs that preserve muscle mass during weight loss. Because losing weight is good, but losing muscle is bad.

ATTAIN-2 results confirmed efficacy in people with type 2 diabetes. Participants on the highest dose lost an average of 22.9 pounds (10.5% of body weight), and HbA1c levels decreased by 1.8% [2].

Here's what Deborah Horn, director of the Obesity Medicine Center at UTHealth Houston, says: 'People with obesity need treatment options that fit their lifestyle. For many, a daily pill without food and water restrictions provides greater flexibility in their treatment approach' [4].

Phase 2 showed weight loss up to 19% over 46 weeks. Phase 3 studies called SYNCHRONIZE are currently underway. Boehringer Ingelheim is evaluating the drug's efficacy and safety in larger patient groups.

When to expect? Realistic approval timeline — 2027-2028. And that's assuming successful completion of Phase 3 without delays. Delays in clinical trials are more the rule than the exception.

Boehringer Ingelheim is a powerful German pharmaceutical company. If survodutide shows good results in SYNCHRONIZE, it could become serious competition for existing drugs. Especially for people with liver problems.

Amycretin (Novo Nordisk): Fast Start and Dual Mechanism

Novo Nordisk, creators of Ozempic and Wegovy, aren't sitting still. Their new molecule amycretin combines GLP-1 with amylin. And the first results are impressive.

In Phase 1 studies, amycretin showed up to 13% weight loss in just 12 weeks. This is an extremely fast start. For comparison: Ozempic typically gives 3-5% over the same period.

Amycretin has advanced to Phase 3 studies for weight loss, where Phase 2 showed 22% weight reduction. This is comparable to Mounjaro results.

Novo Nordisk positions amycretin as a potential replacement for Wegovy. If Phase 3 confirms efficacy and safety, this will be a strong market player. But again — approval isn't expected before 2027-2028.

And while amycretin undergoes trials, Ozempic and Mounjaro are already available. Their effectiveness is proven by years of clinical practice.

CagriSema (Novo Nordisk): Amylin + Semaglutide Combination

Another Novo Nordisk project — CagriSema. This is a combination of cagrilintide (amylin analog) and semaglutide (Ozempic's active ingredient) in one injection. Essentially, two drugs in one syringe.

Phase 3 REDEFINE study results are impressive: 20.4% weight loss over 68 weeks. This is close to Mounjaro's 22.5% results.

Note the last two rows. Mounjaro and Ozempic are the only drugs in this table that are already available. And their efficacy matches most 'drugs of the future.'

Typical Timeline from Phase 3 to Pharmacy: Why the Wait Will Be Long

Many people underestimate how long it takes for a drug to travel from successful study to pharmacy shelf. Let's break it down.

Typical timeline from Phase 1 to FDA approval for obesity drugs is 8-10 years. That's under ideal conditions. And ideal conditions are rare.

Pipeline from Phase 3 to actual approval takes 2-3 years. The FDA needs time to analyze data, may request additional studies, safety questions may arise. Then more time for manufacturing, logistics, obtaining approvals in different countries.

Delays can occur at any stage. Regulatory agencies may request more safety data. Manufacturing capacity may be insufficient (remember the Ozempic shortage in 2023-2024). Supply chain issues may emerge.

And even when a drug hits the market, prices are usually very high for the first years. Insurance companies aren't quick to cover new molecules. Availability is limited.

What This Means for Those Planning to Lose Weight NOW

Let's summarize what we've learned.

First. The GLP-1 drug pipeline is indeed impressive. Orforglipron is already approved in the US [4]. CagriSema, amycretin, survodutide show promising results in clinical trials.

Second. None of these drugs will be available in Ukraine before 2027-2028. Not even orforglipron, which is already FDA-approved.

Third. New drug prices will be high in their first years. That's market law.

Fourth. Mounjaro with 22.5% effectiveness and Ozempic with 14.9% are available right now. Their safety and effectiveness are confirmed by years of real-world use.

While Amycretin and CagriSema undergo Phase 3, the most powerful triple agonist is already available in Ukraine: Retatrutide buy in Ukraine — GLP-1 + GIP + glucagon, average weight reduction -24.2% in Phase 2 (highest rate among injectables for weight loss). DOZA: original, thermal box 2–8 °C, 1–2 days throughout Ukraine.

Ready to start? Browse the catalog or write to our specialist on Telegram @Doza_sofia_bot for a free consultation. Your new figure shouldn't wait until 2028.

Where to Order DOZA Products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Ozempic buy in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for starting dose.
• Cagrilintide (Amylin) buy in Ukraine — amylin analog from Novo Nordisk for prolonged satiety, complement to GLP-1 at plateau.

Where to buy

DOZA supplies the products mentioned in this article with an official cold chain and 24/7 specialist support:

• Buy Mounjaro in Ukraine — DOZA catalog with all 6 doses (2.5–15 mg) and official 24h cold-chain delivery. Current Mounjaro prices.